Prescribing information available here
Adverse event reporting information can be found at the bottom of this page
A common misconception is that dry powder inhalers (DPIs) do not adequately deliver the intended dose. This is far from the truth as 99% of patients, with varying age and disease severity, reach the peak inspiratory flow rate of 30 L/min required for a full and effective dose from Easyhaler®.1 This means that vast majority of patients can receive the full dose of medication via Easyhaler®.1
Bufomix Easyhaler Contraindications and Undesirable effects
Contraindications: Hypersensitivity to the active substances or lactose monohydrate (which contains small amounts of milk protein).
Undesirable effects:
Common (≥1/100 to < 1/10): Candida infections in the oropharynx, pneumonia (in COPD patients) headache, tremor, palpitations, mild irritation in the throat, coughing, dysphonia including hoarseness.
See SmPC for full list of adverse reactions
Date of preparation: October 2024 / EASYH-2723(1)
References
1. Malmberg LP, Pelkonen AS, Vartiainen V et al. Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler® dry powder inhaler: a pooled analysis of two randomized controlled trials. J Thorac Dis. 2021 Feb;13(2):621-631.
DATE OF PREPARATION: MAY 2023/EASYH-688(10)
FULL PRESCRIBING INFORMATION AVAILABLE HERE
For more information about Orion and Sustainability click here
| Adverse effects should be reported. You can report side effects directly via the Health Products Regulatory Authority (HPRA) website: www.hpra.ie or by email on medsafety@hpra.ie. Adverse effects should also be reported to Orion Pharma via ie.medicalinformation@orionpharma.com |
